Use the hyperlinks, where available to access additional clinical trial information.
An Open-Label, Multicenter, Phase Ib Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Anti-Tumor Activity of RO7296682 in Combination With Atezolizumab in Participants With Advanced and/or Metastatic Solid Tumors
This is a dose escalation and expansion trial, being undertaken in three parts (1 - dose escalation, 2 - dose expansion and 3 - exploratory). In part 1, patients with mixed solid tumours will be given ascending doses of RO7296682 with a fixed dose of Atezolizumab every three weeks, until a recommended/maximum tolerated dose is defined. Part 2 & 3 will commence once this dose has been defined. Patients with selected cancer types will be enrolled in part 2 & 3 of the trial and will receive a fixed dose of RO7296682 in combination with Atezolizumab, according to the defined dosing regimen.